The DUSP3 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 human lung adenocarcinoma cell line. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, producing a heterogeneous pool of cells with ablated DUSP3 protein expression. The polyclonal format retains genetic diversity while avoiding biases inherent to clonal selection, making it well-suited for studying DUSP3’s role in MAPK signaling regulation, cell proliferation, and cancer biology.
A-549 cells are an epithelial cell line isolated from human lung adenocarcinoma explant tissue, widely used as a model for alveolar type II pneumocytes and lung cancer. They are employed extensively in respiratory and oncology research to investigate signaling mechanisms underlying carcinogenesis, drug resistance, and cellular responses to growth factors such as EGF and oxidative stress. The robust and reproducible growth characteristics of A-549 cells support a broad range of experimental assays.
DUSP3 encodes a dual-specificity phosphatase that dephosphorylates phosphotyrosine and phosphoserine/threonine residues on the MAP kinases ERK1/2 and JNK, thereby negatively regulating MAPK signaling. Signaling through EGFR, RAS, RAF, and MEK1/2 leads to ERK1/2 activation, while JNK is activated by stress stimuli; DUSP3 directly interacts with ERK2, JNK1, and JNK2 to counteract their phosphorylation. This reduces downstream phosphorylation of transcription factors ELK1 and c-Jun, dampening proliferative and survival transcriptional programs. Consequently, DUSP3 loss causes sustained MAPK pathway activity and enhances cell cycle progression.
Within the A-549 lung adenocarcinoma background??which harbors activating mutations along the EGFR?CRAS?CRAF axis??DUSP3 knockout amplifies ERK1/2 and JNK signaling, reinforcing oncogenic phenotypes such as heightened proliferation, apoptosis resistance, and reduced sensitivity to EGFR inhibitors. This model thus enables mechanistic dissection of how phosphatase dysfunction contributes to lung cancer progression and acquired drug resistance. Moreover, given DUSP3’s role in T cell receptor signaling, these cells can be used to study tumor-immune interactions in co-culture systems.
Researchers can employ this model in a variety of assays, including western blotting for phospho-ERK1/2 and phospho-JNK ELISA to quantify MAPK pathway activation upon stimulation with EGF or oxidative stress. Proliferation (MTT, BrdU) and apoptosis (caspase-3/7 activity) assays directly measure the functional impact of DUSP3 loss, while drug sensitivity testing with EGFR inhibitors (e.g., erlotinib, gefitinib) assesses therapeutic relevance. For further details or to place an order, please contact Ascent Research.
